Lilly adds 12.5 mg and 15 mg Zepbound vials, making all six doses available self-pay for $499 or less

Eli Lilly said on June 16, 2025 that it will sell the 12.5 mg and 15 mg doses of Zepbound (tirzepatide) as single-dose vials through LillyDirect's Self Pay Pharmacy Solutions, at $499 a month ^[3]. Adding those two strengths means every approved dose of the drug is available in vial form at $499 a month or less, regardless of insurance status, for eligible adults with obesity and a valid prescription ^[3].

Health care providers could begin prescribing the 12.5 mg and 15 mg vials on July 7, 2025, and shipments to patients were set to start in early August ^[3].

The two new vials fall under the Zepbound Self Pay Journey Program. Under that program, the regular monthly prices for the 7.5 mg, 10 mg, 12.5 mg and 15 mg doses are $599, $699, $849 and $1,049 — but those doses cost $499 for the first fill and for refills made within 45 days of the previous delivery ^[3]. The 2.5 mg starter dose costs $349 for the first month, and the 5 mg dose, the next step in treatment, costs $499 a month ^[3].

In a later announcement dated Dec. 1, 2025, Lilly lowered those program prices to $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg ^[2]. That announcement also noted that if the 12.5 mg or 15 mg vials are refilled outside the 45-day window, the price returns to $849 and $1,049 respectively ^[2].

"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, group vice president of U.S. Cardiometabolic Health at Lilly. "Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound" ^[3]. In the December announcement, Ilya Yuffa, executive vice president and president of Lilly USA, said "far too many people who need obesity treatments still face cost and coverage barriers" ^[2].

Zepbound is a dual GIP and GLP-1 receptor agonist approved on Nov. 8, 2023 for chronic weight management in adults with obesity, or adults with overweight who also have at least one weight-related medical condition ^[1]. It was later approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity ^[1]. In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 pounds) at 5 mg, 19.5% (44 pounds) at 10 mg, and 20.9% (48 pounds) at 15 mg, compared with 3.1% (7 pounds) on placebo ^[3]. In a separate 72-week study of adults with diabetes, average loss was 12.8% (28 pounds) at 10 mg and 14.7% (33 pounds) at 15 mg, compared with 3.2% (7 pounds) on placebo ^[3]. Lilly states that individual results vary and that Zepbound is not for cosmetic weight loss ^[3].

The drug already was sold in single-dose pens (autoinjectors) in the same six strengths ^[3]. Recommended dosing starts at 2.5 mg once weekly for four weeks, then 5 mg, with increases of 2.5 mg no sooner than every four weeks; 2.5 mg is not an approved maintenance dose and the maximum dose is 15 mg ^[3]. Zepbound carries a boxed warning for the risk of thyroid C-cell tumors, and it should not be used with other tirzepatide products or any GLP-1 receptor agonist medicine ^[1][3].

Why it matters for patients

The vials create a cash-pay route to every Zepbound dose that does not depend on a prior authorization or an insurer's decision to cover an obesity medicine ^[3]. For people whose plan does not cover the drug, or who do not want to use insurance for it, the advertised monthly price is $499 or less, rather than the $849 and $1,049 regular monthly prices listed for the two highest doses ^[3].

That price is conditional. The reduced rate for the 7.5 mg through 15 mg vials applies to the first fill and to refills made within 45 days of the previous delivery; a refill outside that window is charged at the regular price ^[2]. Patients who order later than that may pay substantially more in a given month.

The vials are also a different delivery format from the autoinjector pens, which remain available in the same strengths ^[3]. Lilly has published guidance on appealing coverage denials and submitting letters of medical necessity at Zepbound.lilly.com ^[3].

What happens next

• July 7, 2025: health care providers could begin prescribing the 12.5 mg and 15 mg single-dose vials ^[3].
• Early August 2025: shipments of those two doses to patients were expected to begin ^[3].
• Dec. 1, 2025: Lilly announced lower self-pay vial prices, including $299 for the 2.5 mg starting dose and $449 for all other approved doses under the Journey Program ^[2].

Whether insurers will cover the vial versions of Zepbound, and whether the self-pay prices will change again, has not been disclosed ^[3][2].